Voyager Therapeutics received IND clearance from the FDA for VY-1706, an investigational gene therapy targeting intracellular and extracellular tau for Alzheimer’s disease. The company said the regulatory milestone advances its tau-directed strategy into planned clinical development steps. VY-1706 is designed to address tau pathology by modulating tau spread and accumulation across disease-relevant compartments, aligning with a broader field shift toward targeting the biology underlying neurodegeneration rather than only symptom management. For industry stakeholders, IND clearance is a gating milestone that can accelerate recruitment, inform manufacturing readiness and set expectations for early biomarker strategies. The clearance also adds to the growing tau gene therapy pipeline as more programs compete to establish clinically meaningful readouts in Alzheimer’s disease trials.